Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alzamend Neuro, Inc

5.15
-0.7729-13.05%
Post-market: 5.490.3385+6.57%19:46 EDT
Volume:159.67K
Turnover:861.84K
Market Cap:4.12M
PE:-0.36
High:5.79
Open:5.58
Low:5.03
Close:5.92
Loading ...

Alzamend Neuro Inc - Reverse Split to Maintain Nasdaq Listing Compliance

THOMSON REUTERS
·
08 May

Alzamend Neuro Inc - Approves One-for-Nine Reverse Stock Split

THOMSON REUTERS
·
08 May

Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March?

Insider Monkey
·
28 Mar

Alzamend Neuro announces initiation date of Phase II trial of AL001

TIPRANKS
·
26 Mar

Alzamend Neuro Announces Initiation Date of Phase Ii Clinical Trial of Al001 for Treatment of Alzheimer’s Disease to Take Place at Massachusetts General Hospital

THOMSON REUTERS
·
25 Mar

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital

GlobeNewswire
·
25 Mar

Alzamend Neuro Inc: Plans to Initiate Phase Ii Clinical Study of Al001 for Treatment of Patients With Mdd in Q4 of 2025

THOMSON REUTERS
·
18 Mar

Alzamend Neuro announces initiation of Phase II trial of AL001

TIPRANKS
·
11 Mar

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

GlobeNewswire
·
11 Mar

Alzamend Neuro Announces Initiation Date of Phase Ii Clinical Trial of Al001 for Treatment of Bipolar Disorder to Take Place at Massachusetts General Hospital

THOMSON REUTERS
·
04 Mar

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

GlobeNewswire
·
04 Mar

Ambarella Appoints Chantelle Breithaupt as Independent Director

TIPRANKS
·
01 Mar

Alzamend Neuro (ALZN) Gets a Hold from Maxim Group

TIPRANKS
·
27 Feb

Alzamend Neuro Announces Initiation Date of First Phase Ii Clinical Trial of Al001 to Take Place at Massachusetts General Hospital

THOMSON REUTERS
·
25 Feb

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

GlobeNewswire
·
25 Feb

EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025

Benzinga
·
25 Feb

BRIEF-Alzamend Neuro Announces Completion Of A Novel Head Coil By Tesla For Measuring Brain Structure Lithium Levels In Five Upcoming Phase Ii Clinical Trials At Massachusetts General Hospital

Reuters
·
19 Feb

Alzamend Neuro announces completion of head coil by Tesla Dynamic Coils

TIPRANKS
·
19 Feb